About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Avacta Appoints Brian Hahn as Chief Financial Officer

LONDON and PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Brian Hahn as Chief Financial Officer (CFO).

Mr Hahn brings more than 25 years of senior financial and operations experience in the biopharmaceutical industry, including a 15-year tenure as CFO and Senior Vice President of GlycoMimetics, Inc., where he led the company’s 2014 initial public offering (IPO) on Nasdaq and the build-out of its finance, accounting, investor relations and corporate affairs functions.

He has worked with life science companies from early stages through product launch, has significant experience in dealing with US healthcare investors, having been involved in multiple IPOs, and has raised over $700 million in capital. He has broad experience in developing strategic plans, business development deals, building strong organizations and establishing strong accounting and control systems which ensure Sarbanes-Oxley compliance.

Mr Hahn currently serves as co-chairman of the BIO Finance and Tax Committee, as a co-chairman of the Steering Committee of the Washington, DC chapter of the Association for Bio Financial Officers (ABFO) and has also served on the Securities and Exchange Commissions’ Advisory Committee on Small and Emerging Companies. Prior to his 15-year tenure at GlycoMimetics, Mr. Hahn held roles of increasing financial leadership responsibility, including Executive Director of Finance at MiddleBrook Pharmaceuticals (formerly Advancis Pharmaceutical), and earlier, Senior Accountant with Bering Truck Corporation.

He received a B.B.A. in Accounting from Shenandoah University and an M.B.A. from the University of Maryland.

“Brian brings the ideal combination of deep public company experience and understanding of the biotechnology sector that Avacta needs at this transformative stage,” said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta. “His strategic insight and track record of successful financial leadership in clinical-stage companies will be essential as we advance our promising pipeline and prepare for our next phase of growth, including our potential dual listing on the Nasdaq exchange.”

“What drew me to Avacta was not just the company’s innovative technology platforms. It also has a clear vision for revolutionizing cancer treatment through targeted therapies that improve outcomes for patients and their families,” commented Brian Hahn. “The company has built a strong foundation with its pre|CISION® and Affimer® platforms, and I look forward to leveraging my experience to help accelerate Avacta’s growth and strengthen its position in both the U.K. and U.S. capital markets.”

For further information from Avacta, please contact:

Avacta Group plc
Michael Vinegrad, Group Communications
Director
www.avacta.com
  
Peel Hunt (Nomad and Broker)
James Steel / Chris Golden / Patrick Birkholm
www.peelhunt.com

  
ICR Healthcare
Mary-Jane Elliott / Jessica Hodgson / Max Bennett
avacta@consilium-comms.com
  
Investor Contact
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com

  
Media Contact
Carly Scaduto
Carly Scaduto Consulting
Carly@carlyscadutoconsulting.com

About Avacta www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.


Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.